BRIACELL THERAPEUTICS CORP. Depreciation and Amortization
BRIACELL THERAPEUTICS CORP. (BCTX) reported Depreciation and Amortization of $11.45 thousand for the 9-month period ending 2023-04-30, per its 10-Q filed 2023-06-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2023-06-14
- BRIACELL THERAPEUTICS CORP. depreciation, depletion and amortization for the quarter ending 2023-04-30 was $3.82K, a 0.03% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. depreciation, depletion and amortization for the quarter ending 2023-01-31 was $3.82K, a 0.05% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. depreciation, depletion and amortization for the quarter ending 2022-10-31 was $3.82K, a 0.03% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. depreciation, depletion and amortization for the quarter ending 2022-07-31 was $3.82K.
- BRIACELL THERAPEUTICS CORP. depreciation, depletion and amortization for fiscal 2022 was $15.27K, a 0.10% increase from fiscal 2021.
- BRIACELL THERAPEUTICS CORP. depreciation, depletion and amortization for fiscal 2021 was $15.26K.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2023-04-30 | $3.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | $7.63K derived: sum of 2 quarters · filed 2023-06-14 | $11.45K 10-Q · filed 2023-06-14 | $15.27K derived: sum of 4 quarters · filed 2023-06-14 |
| 2023-01-31 | $3.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | $7.63K 10-Q · filed 2023-03-16 | $11.45K derived: sum of 3 quarters · filed 2023-03-16 | $15.27K derived: sum of 4 quarters · filed 2023-06-14 |
| 2022-10-31 | $3.82K 10-Q · filed 2022-12-14 | $7.64K derived: sum of 2 quarters · filed 2022-12-14 | $11.45K derived: sum of 3 quarters · filed 2023-06-14 | $15.27K derived: sum of 4 quarters · filed 2023-06-14 |
| 2022-07-31 | $3.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-28 | $7.64K derived: sum of 2 quarters · filed 2023-06-14 | $11.46K derived: sum of 3 quarters · filed 2023-06-14 | $15.27K 10-K · filed 2022-10-28 |
| 2022-04-30 | $3.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | $7.64K derived: sum of 2 quarters · filed 2023-06-14 | $11.45K 10-Q · filed 2023-06-14 | |
| 2022-01-31 | $3.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | $7.64K 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $3.82K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | $15.26K 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |